

Title (en)

Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases

Title (de)

Arylsubstituierte Azabenzimidazole und ihre Verwendung bei der Behandlung von HIV und AIDS-verwandten Erkrankungen

Title (fr)

Azabenzimidazoles ayant des substituants aryles et leur utilisation pour le traitement de VIH et de maladies relatives au SIDA

Publication

**EP 1125936 A3 20020724 (EN)**

Application

**EP 01300599 A 20010124**

Priority

US 17792000 P 20000125

Abstract (en)

[origin: US6242461B1] This invention relates to novel aryl substituted azabenzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof wherein  $R_1$  is an integer from 1 to 4;  $X$  is CH or N;  $R_1$  is H, (C1-C6)alkyl or (C1-C6) alkoxy;  $R_2$  is H, (C1-C6)alkyl or (C1-C6) alkoxy; each  $R_3$  is independently selected from H, (C1-C6)alkyl (C1-C6) alkyloxy, (C1-C6) alkylthio, halo, nitro, cyano, ethynyl, hydroxy and trifluoromethyl;  $R_4$  is H, (C1-C6)alkyl or (C1-C6) alkoxy;  $R_5$  is H, (C1-C6)alkyl or (C1-C6) alkyloxy, trifluoromethyl; and  $W$  is N or C;  $Y$  is N ( $R_4$ ), N, S or OZ is R4, NR4H, O, or OH; Provided that when  $Y=NR_4$ ,  $W=C$ ,  $Z=O$ , there is a single bond between  $YW$  and a double bond between  $WZ$ ; and when  $Y=O$  or S,  $W=C$ ,  $Z=O$ , there is a single bond between  $YW$  and a double bond between  $WZ$ ; and when  $Y=N$ ,  $W=N$ , there is a double bond between  $YW$  and  $Z$  does not exist. When  $Y=N$ ,  $W=C$ ,  $Z=R_4$  or NHR4, there is a double bond between  $YW$  and a single bond between  $WZ$ ; The methods of preparing these compounds and their use in the treatment of HIV, AIDS, and AIDS related diseases and in slowing the progression of HIV infection into AIDS is also disclosed.

IPC 1-7

**C07D 471/04; A61K 31/437; A61P 31/18**

IPC 8 full level

**C07D 471/04** (2006.01); **A61K 31/437** (2006.01); **A61K 31/444** (2006.01); **A61K 45/06** (2006.01); **A61P 11/00** (2006.01); **A61P 17/06** (2006.01); **A61P 31/10** (2006.01); **A61P 31/18** (2006.01); **A61P 33/02** (2006.01); **A61P 33/08** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP US)

**A61K 31/437** (2013.01 - EP US); **A61K 31/444** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 11/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 31/10** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 33/08** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)

- [X] WO 9117162 A1 19911114 - PFIZER LTD [GB], et al
- [A] WO 9837072 A1 19980827 - US HEALTH [US], et al
- [A] WO 9959585 A1 19991125 - PROCTER & GAMBLE [US], et al
- [A] US 5935982 A 19990810 - DYKSTRA CHRISTINE C [US], et al
- [A] EP 0706795 A2 19960417 - PFIZER [US]
- [AD] US 5322847 A 19940621 - MARFAT ANTHONY [US], et al

Cited by

EP2326631A4; US9643922B2; US7375118B2; US7256287B2; US7282518B2; US9540322B2; US10202343B2; US11584717B2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

**US 6242461 B1 20010605**; BR 0100155 A 20010828; CA 2332087 A1 20010725; CA 2332087 C 20041123; EP 1125936 A2 20010822; EP 1125936 A3 20020724; JP 2001226374 A 20010821; JP 2004002483 A 20040108; JP 3489821 B2 20040126

DOCDB simple family (application)

**US 57865500 A 20000525**; BR 0100155 A 20010125; CA 2332087 A 20010123; EP 01300599 A 20010124; JP 2001016524 A 20010125; JP 2003320650 A 20030912